This study is testing MultiStem®, a biological treatment, or a placebo (an inactive substance) in severely injured trauma patients. You might be able to join if you are 18 or older, have received at least 3 units of blood products before arriving at the Shock Trauma Intensive Care Unit (STICU), and your initial bleeding has been controlled. Doctors also need to believe you will survive at least 24 hours after STICU arrival. The main goal is to see if MultiStem® can help prevent or reduce the severity of acute kidney injury (kidney damage) within 30 days after treatment. The current status of this study is unclear.

Study design

This is a Phase 2, single-center study that will randomly assign participants to receive either MultiStem® or a placebo. It is double-blind, meaning neither you nor your doctors will know which treatment you are receiving. The study plans to enroll 156 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at Day 30, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.